Driving Sustainable Expansion and Excellence!

 

Have you ever wondered how pharmaceutical companies identify areas for growth and expansion? As the pharmaceutical industry continues to evolve and expand, companies are constantly searching for new areas of growth and development. But how do they identify these opportunities? The answer is not a simple one and involves a complex process of research, analysis, and strategic planning.

EQL Pharma is one such company that has a unique strategy for developing and marketing generic drugs. With a focus on efficiency and thoughtfulness, EQL Pharma aims to tap into markets with strong potential for profitable growth. But what sets them apart is their willingness to explore different therapy areas, product groups, and geographies, thereby expanding their horizons with no limits to their potential.

Under the exceptional leadership of President and CEO Axel Schörling, it has carved a unique path in the pharmaceutical industry. With a sharp focus on developing and marketing generic drugs in untapped markets, EQL Pharma has positioned itself for remarkable growth. Guided by a commitment to sustainability and profitability, the company's strategic location and strong network have propelled them to the forefront of the industry.

Its core mission is to identify therapies and markets with substantial growth potential. By capitalizing on areas where generic competition is weak or absent, the company has established a niche for itself. Additionally, EQL Pharma seeks to address specific therapy needs or target patient groups through innovative formulations. This broad approach allows the company to explore diverse therapy areas, product groups, and geographies, fostering long-term success.

Strategically based in Lund, EQL Pharma benefits from the thriving life science cluster known as Medicon Valley. This prime location grants the company access to a wealth of resources, including world-class organizations, companies, and talented individuals. Through strategic partnerships and an expanding network, EQL Pharma continuously refines its connections, embracing new ideas and seizing opportunities for growth.

EQL Pharma's vision centers on strong and sustainable growth. Each investment in the company's pipeline and expansion into new markets is meticulously planned and backed by robust financing and thorough analysis. By employing a diligent and forward-thinking approach, EQL Pharma navigates the pharmaceutical landscape with confidence and resilience.

It recognizes that its success rests on the caliber of its personnel. The company strives to attract and retain professionals who excel in all areas relevant to the organization. With a commitment to a high level of education, solid experience, and unwavering personal dedication, EQL Pharma's team fosters stability and continuity amidst rapid growth. This cohesive workforce ensures that the company remains at the forefront of pharmaceutical excellence.

Axel’s strategic vision, coupled with a commitment to sustainable growth and innovation, has propelled the company to new heights. Schörling's guidance ensures that EQL Pharma remains at the forefront of the industry, consistently exploring new opportunities, and making a positive impact on patients' lives.

 

Let us delve further into their triumphant voyage towards sustainability and eminence!

 

Path to Successful Leadership

According to Axel, leadership involves engagement and empowerment, which he believes is a significant aspect of the Northern European leadership style. The primary focus of this approach is to create a positive and supportive work culture. Axel thinks that having a work environment where team members feel engaged, involved, and empowered helps maximize their potential. The organization where Axel works is small and flat, and most team members understand the big picture of the company's success and the outcomes of their collective efforts. It's not only Axel and the CFO who know the strategic direction and priorities; the team members are also aware of them. Axel aims to maintain transparency in his leadership style so that the team knows where they are going and can make decisions that align with the company's long-term goals at both individual and organizational levels.

 

Value System Driving Success

Their value system emphasizes the importance of transparency. They have a hands-on approach to problem-solving, which they call "Rolling up their sleeves and getting things done." They avoid getting bogged down by excessive analysis and evaluation and instead prioritize taking action. In their line of work in the pharmaceutical industry, they prioritize delivering high-quality products that provide care and service to their customers. They recognize the responsibility that comes with producing products that people consume in hopes of being cured, and they never compromise on quality or take shortcuts.

 

Power of Purpose

Their contribution to society can be divided into two components. Firstly, for the niche generic segment, the patent expiration doesn't result in significant price drops as compared to other generic products. In the case of other generic products with many competitors, there is a substantial decrease in prices, leading to savings for patients and payers. For niche products, the price drop is around 20 or 30 percent after the patent expiration. They enter the market and push the price further down, making pharmaceuticals more affordable for patients, society, and taxpayers.

Secondly, as these niche products are uncommon, there is a risk that they may not reach the patient in the absence of one or two suppliers. Therefore, they build a robust system to ensure that essential pharmaceuticals reach the patients who need them.

Lastly, they have a product called Mellozzan, which is a melatonin-based product used to treat insomnia in children with ADHD. It is a disorder that affects the whole family, and this product helps overactive children have a good night's sleep, leading to a better quality of life. They can focus on their studies, do their homework, and function healthily. It is a product that they are particularly proud of.

 

Striking a Balance

Axel values work-life balance and recognizes its significance in his life. Although he knows some colleagues who are motivated and engaged while working for only 40 hours per week, Axel tends to put in a little extra effort. However, he makes sure to incorporate physical workouts and prioritize his sleep. Axel also strives to keep his weekends free from work so he can enjoy quality time with his family and the outdoors. Additionally, he has begun practicing mental strengthening techniques such as meditation and cognitive exercises.

 

Role of Technology and Innovation

The focus of their efforts is not on technological innovation per se, but rather on commercial innovation. Their success depends on innovation, and they work closely with their business development team to brainstorm new and clever business models. Additionally, they are constantly observing the pharmaceutical industry in other countries and adopting successful practices to expand their innovation processes.

 

One Word That Defines Axel

Axel characterizes himself as "Driven." He attributes this to his abundant energy for work and his belief that working is enjoyable. Axel is constantly seeking new ideas and pushing himself and his colleagues to enhance the business, and he is determined to discover smarter and more cost-efficient methods to accomplish tasks. It is therefore reasonable to conclude that Axel possesses a great deal of energy and is highly motivated.

 

Potential for Growth and Success

Axel is fully committed and overjoyed with his position at EQL Pharma. His confidence in the company's strategic vision and the team is unwavering. He passionately desires to remain with his colleagues and work towards building a thriving pharmaceutical enterprise.

 

Mastermind Behind EQL Pharma's Phenomenal Triumph

EQL Pharma's CEO, Axel Schörling, holds dual master's degrees in engineering physics and financial economics. Prior to joining EQL, he spent five years in management consulting, where he specialized in operations and supply chains. He then transitioned to business control for two years before joining EQL as their Chief Operating Officer in 2018. After being promoted to Deputy CEO in 2020, Axel was appointed as EQL Pharma's CEO in 2022.